Lymphoma Diagnosis and Management: Long-Term Complications Faced by Survivors

By Andreas Vogiatzis — Medical Student, MUS | UTH

Introduction

Lymphomas, including Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), represent a significant group of hematologic malignancies worldwide.

Advances in diagnostic tools, chemotherapy protocols (e.g., ABVD and CHOP), immunotherapies, and hematopoietic stem cell transplantation have markedly improved survival rates over the past decades.

However, for many survivors — especially adolescents and young adults — remission is only the beginning of a long-term health journey. Complications affecting the cardiovascular system, endocrine function, risk for secondary malignancies, and psychological well-being remain prevalent.

Get Andreas Vogiatzis’s stories in your inbox

Join Medium for free to get updates from this writer.

Remember me for faster sign in

This article reviews current guidelines for lymphoma diagnosis and treatment, with a special emphasis on the often-overlooked survivorship phase.

Diagnosis: Then and Now

The diagnosis of lymphoma has undergone significant changes. While excisional biopsy remains the gold standard, modern procedures usually include:

• Immunophenotyping (e.g., CD20, CD3, CD30 markers)
• PET-CT scans for functional staging and treatment response
• Molecular profiling and gene expression analysis, including cell-of-origin subtyping in diffuse large B-cell lymphoma (DLBCL)

Precise subtyping enables better risk stratification and guides personalized treatment strategies.

Management Strategies

Common frontline regimens include:

• ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) — Standard for HL
• CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) — For aggressive NHL
• R-CHOP — Addition of Rituximab improves outcomes in CD20+ NHL

Treatment escalation options:

• Autologous/allogeneic stem cell transplantation
• CAR-T cell therapy for relapsed or refractory B-cell lymphomas

The Forgotten Phase: Survivorship

Despite curative therapy, many survivors face persistent or late-onset complications:

1. Cardiovascular Risk

• Anthracycline-induced cardiotoxicity (e.g., Doxorubicin) may lead to cardiomyopathy or ischemic heart disease.
• Surveillance: Routine echocardiography in high-risk individuals is recommended.

2. Neurocognitive Effects

• “Chemobrain”: memory impairment, attention deficits, and reduced executive function.
• Exacerbated by CNS-directed or high-dose regimens.

3. Secondary Malignancies

• HL survivors exposed to radiation or alkylating agents are at increased risk for breast, lung, and hematologic cancers.
• Screening recommendation: Breast cancer screening at age 25 or 8 years post-radiation (whichever comes first).

4. Endocrine and Fertility Issues

• Hypothyroidism in patients receiving neck irradiation
• Gonadal failure due to alkylating agents
• Fertility preservation strategies should be offered before treatment

5. Psychosocial Challenges

• High rates of PTSD, anxiety, and depression
• Survivors often face employment challenges and insurance discrimination
• Essential to implement structured survivorship care plans, including access to mental health services

Recommended Follow-Up Includes:

• Annual CBC and thyroid function tests
• Echocardiography based on exposure to cardiotoxic agents
• Routine psychosocial screening
• Lifestyle interventions (smoking cessation, exercise, etc.)

Conclusion

While curative treatments for lymphoma have advanced significantly, long-term survivorship care remains an essential yet underappreciated aspect of patient management.
Early recognition and intervention for late complications can improve both life expectancy and quality of life for survivors.

References
1. Hodgson DC, et al. Breast Cancer After Treatment for Hodgkin’s Lymphoma. J Clin Oncol. 2007.
2. Mulrooney DA, et al. Cardiac Outcomes in Survivors of Childhood Cancer. J Clin Oncol. 2009.
3. Casillas J, et al. Long-term Follow-up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Pediatrics. 2021.
4. Smith SM, et al. Survivorship Issues in Hematologic Malignancy. Hematology Am Soc Hematol Educ Program. 2018.
5. ASCO Survivorship Guidelines — www.asco.org

Written by Andreas Vogiatzis — Medical Student with a clinical interest in oncology and general surgery
Medical University of Sofia (MUS) | University of Thessaly (UTH)
🔗 LinkedIn | X (formerly Twitter)

Andreas Vogiatzis

Medical Student | Medical University — Sofia (MUS), Faculty of Public Health • University of Thessaly (UTH)

ΒΟΓΙΑΤΖΗΣ ΑΝΔΡΕΑΣ

ΦΟΙΤΗΤΗΣ ΙΑΤΡΙΚΗΣ